chronic subdural hematoma
Conditions
Interventions
Naoxue Shu oral liquid treatment group:Naoxueshu Oral Liquid taken orally, 10ml each time, 3 times a day, for 90 days
Sponsors
Beijing Tiantan Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 89 Years
Inclusion criteria
Inclusion criteria: ? Age =18 and <89 years old; ? Diagnosedwith CSDH using head computed tomography (CT) scans ormagnetic resonance imaging; ? Markwalder grade scale = 2 and Glasgow scores = 13; ? Neurosurgeon made a judgment that cerebral hernia would not occur and surgical operation might not be performed in a short time, or patient refused surgical treatment; ? No signs of cerebral hernia; ? Patients provided written informed consent.
Exclusion criteria
Exclusion criteria: ?Known hypersensitivity to any ingredients of Naoxueshu oral liquid; ?Removal surgery for tracranial hematoma has been planned within 15 days; ?Hematoma caused by tumors, blood and other known comorbidities; ?Patients had been on oral Steroids for >1 week; ?Patients had been on oral Statin for >1 week; ?Patients with abnormal platelet count or coagulation function; ?Chronic liver disease, liver and kidney dysfunction, elevated ALT ( >3 times the upper limit of normal value), elevated blood creatinine (> 2 times the upper limit of normal value); ?Patients with heart and lung dysfunction; ?Patients with a tendency towards severe bleeding or re bleeding; ?Patients may receive unconventional anticoagulant treatment with ordinary heparin or low molecular weight heparin during the trial process; ?Patients with an expected lifespan of less than 1 month or those who are unable to complete the study for other reasons; ?Pregnant or breastfeeding; ?Participation in clinical studies of other investigational drugs within 30 days; ?Unable to understand and/or comply with research procedures and/or follow-up due to mental illness, cognitive or emotional disorders; ?For any reason, the researchers believe that the case is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematoma volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| Markwalder grading scale;Barthel Index;recurrence; | — |
Countries
China
Contacts
Public ContactFan Yongping
Beijing Tiantan Hospital Affiliated to Capital Medical University
Outcome results
None listed